Jagsonpal Pharmaceuticals Analyst Review May 2026
- May 19, 2026
- Posted by: Neeraj Pandey
- Category: News
This Jagsonpal Pharmaceuticals analyst review for May 2026 covers the key data investors need for JAGSNPHARM at its current price of Rs 405. Jagsonpal Pharmaceuticals (NSE: JAGSNPHARM) is a branded pharmaceutical company with a market capitalisation of approximately Rs 700 crore, focused on therapeutic segments including gynaecology, dermatology, and nutraceuticals. The analyst consensus target of Rs 480 implies meaningful upside, and this Jagsonpal Pharmaceuticals analyst review examines technical levels, business segments, valuation, and key risks for JAGSNPHARM through FY27.
Click Here – Get Free Investment Predictions
Jagsonpal Pharmaceuticals Company Snapshot May 2026
Jagsonpal’s branded prescription business in gynaecology and dermatology grows at 12 to 15 percent YoY. The nutraceuticals and dietary supplements segment under the Jagsonpal brand is a new high-growth area. The table below summarises the key data referenced in this Jagsonpal Pharmaceuticals analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | JAGSNPHARM |
| Sector | Pharmaceuticals – Branded Formulations |
| CMP (May 2026) | Rs 405 |
| 52 Week High | Rs 595 |
| 52 Week Low | Rs 338 |
| Market Cap | Rs 700 Crore |
| Trailing P/E | 18x |
| Analyst Consensus Target | Rs 480 |
| Bull Case Target | Rs 620 |
| Bear Case Target | Rs 330 |
Analyst Insight in This Jagsonpal Pharmaceuticals Analyst Review
Associate Director Kunal Singla suggests watching Jagsonpal Pharmaceuticals closely in May 2026. At Rs 405, Kunal Singla flags Pharmaceuticals – Branded Formulations sector dynamics as the primary driver for JAGSNPHARM’s near-term price action. He notes support in the Rs 345 to Rs 385 zone and flags any sustained close above Rs 429 as a positive signal. Kunal Singla’s perspective on Jagsonpal Pharmaceuticals adds professional analysis to this Jagsonpal Pharmaceuticals analyst review and is not a buy recommendation.
Technical Analysis in This Jagsonpal Pharmaceuticals Analyst Review
At Rs 405, JAGSNPHARM is trading within its 52-week band of Rs 338 to Rs 595. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 345 to Rs 385 band while resistance is seen in the Rs 429 to Rs 442 zone. A sustained move above Rs 429 could open the path toward the analyst consensus target of Rs 480 as outlined in this Jagsonpal Pharmaceuticals analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 345 to Rs 385 – investors tracking this Jagsonpal Pharmaceuticals analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for JAGSNPHARM.
- Resistance Zone: Rs 429 to Rs 442 – a sustained close above Rs 429 would be a positive breakout signal worth flagging in this Jagsonpal Pharmaceuticals analyst review.
- Medium-Term Target: The analyst consensus of Rs 480 represents the base-case upside scenario in this Jagsonpal Pharmaceuticals analyst review.
Business Segment Analysis
Branded Pharmaceuticals (Gynaecology and Dermatology)
This is the primary revenue and margin driver for Jagsonpal Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 480.
Nutraceuticals and Dietary Supplements
This segment adds scale and diversification to Jagsonpal Pharmaceuticals’s business model and is a meaningful EPS contributor through FY27 and FY28.
Contract Manufacturing and APIs
This represents the medium-term growth frontier for Jagsonpal Pharmaceuticals and a key re-rating catalyst over the next 12 to 24 months.
Valuation in This Jagsonpal Pharmaceuticals Analyst Review
At Rs 405, Jagsonpal Pharmaceuticals trades at a trailing P/E of 18x. This Jagsonpal Pharmaceuticals analyst review presents three scenarios: a bull case of Rs 620 on strong earnings delivery and sector tailwinds, a base case of Rs 480 at analyst consensus, and a bear case of Rs 330 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Jagsonpal Pharmaceuticals analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 620 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 480 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 330 | Earnings miss or macro headwinds |
Trade Outlook for Jagsonpal Pharmaceuticals
Based on the technical and fundamental analysis in this Jagsonpal Pharmaceuticals analyst review, investors might watch JAGSNPHARM near the support zone of Rs 345 to Rs 385 for potential opportunities. A flag above Rs 429 could suggest improving momentum toward Rs 480. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Jagsonpal Pharmaceuticals in FY27
A well-rounded Jagsonpal Pharmaceuticals analyst review must assess downside risks. Key risks for Jagsonpal Pharmaceuticals include a macro slowdown affecting Pharmaceuticals – Branded Formulations sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in JAGSNPHARM.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Jagsonpal Pharmaceuticals Analyst Review Verdict for 2026
This Jagsonpal Pharmaceuticals analyst review concludes that at Rs 405, JAGSNPHARM offers a defined risk-reward with a consensus target of Rs 480. The 52-week range of Rs 338 to Rs 595 provides context on the current entry point. Use this Jagsonpal Pharmaceuticals analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on JAGSNPHARM.
Frequently Asked Questions: Jagsonpal Pharmaceuticals Analyst Review 2026
What is the analyst target for Jagsonpal Pharmaceuticals in 2026?
The analyst consensus target is Rs 480, with a bull case of Rs 620 and a bear case of Rs 330. This Jagsonpal Pharmaceuticals analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Jagsonpal Pharmaceuticals a good investment at Rs 405?
At Rs 405 with a P/E of 18x and a consensus target of Rs 480, this Jagsonpal Pharmaceuticals analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Branded Formulations sector. Always consult a SEBI-registered advisor before investing.
What is Jagsonpal Pharmaceuticals’s 52-week high and low?
The 52-week high is Rs 595 and the 52-week low is Rs 338. At Rs 405, JAGSNPHARM is positioned within this range as detailed in this Jagsonpal Pharmaceuticals analyst review.
What are the key risks for Jagsonpal Pharmaceuticals?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Branded Formulations sector, all assessed in this Jagsonpal Pharmaceuticals analyst review.
Where can I track live data for Jagsonpal Pharmaceuticals?
Track Jagsonpal Pharmaceuticals’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Jagsonpal Pharmaceuticals analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
